The Board's Guide to Fractional Executive Leadership in Life Sciences
Research-backed analysis for biotech executives, investors, and boards evaluating executive leadership options.
36%
of U.S. workers now identify as independent — McKinsey 2022
90%
of business leaders see competitive advantage in blended talent — HBS & BCG
40%
of senior external hires fail within 18 months — Heidrick & Struggles
$80B
global CRO market — the outsourced leadership model life sciences already trusts
Executive summary
Life sciences companies have long treated senior leadership as a binary choice: hire a full-time executive, or bring in a consultant. For a pre-commercial biotech running on milestones and finite runway, that binary is a poor fit.
A fractional executive is an experienced operating leader who takes a defined executive mandate on a non-full-time basis — holding decision rights and accountability for outcomes. The model differs from consulting, which stops at recommendations, and from interim leadership, which replaces a departed executive.
The central message for a board: employment classification does not, by itself, create accountability or reduce risk. Accountability is governed by how a role is designed — mandate, decision rights, KPIs, and oversight — not payroll status.
The workforce model has changed
Why fractional is emerging now
Accountability vs. employment status
Decision logic: capacity, capability, timing
Life sciences already runs on this model
What a fractional executive is (and isn't)
Common objections addressed
When fractional is right — and when it's not
About the authors
Fractional Executives in Life Sciences
Research-backed market education — no vendor promotion, no sales language
Prepared as neutral thought-leadership for boards, investors, and chief executives. Draws on research from McKinsey, Deloitte, PwC, Harvard Business School, and BCG. Covers workforce trends, life sciences outsourcing models, executive hiring risk, and decision frameworks for leadership design.